Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Elevated IOP due to either primary open-angle glaucoma or ocular hypertension~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimatoprost 0.01% (Naive Monotherapy) (Type: EXPERIMENTAL): 1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.
- Bimatoprost 0.01% (Switched Monotherapy) (Type: EXPERIMENTAL): 1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.
- Bimatoprost 0.01% (with Adjunctive Therapy) (Type: EXPERIMENTAL): 1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).